CSL’s Gene Therapy Approval Marks First for Hemophilia B and New High in Pricing

💡 This post was automatically imported from MedCity News. You can find the original article here.
Author: Frank Vinluan

CSL Behring’s hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics.

You may also like...

Welcome to MediFormatica. The site is still under construction so there are some rough edges here and there, but I'll be adding new and exciting content every day. So enjoy it and come back again for more great stuff.